Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disproxil

- PMLiVE

Brazil: Patient access and education in type 2 diabetes

As the prevalence of diabetes increases in Brazil, the healthcare system needs to respond 

- PMLiVE

Novo opens doors on new US headquarters

$225m redevelopment for New Jersey life science offices

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

Sanofi supports Clexane with Spanish VTE apps

The free iPhone, iPad and Android apps are for healthcare professionals

- PMLiVE

Sanofi’s four-strain flu vaccine Vaxigrip under review in EU

Pharma company also launches production of ingredient for malaria drug

- PMLiVE

Gilead files oral hepatitis C drug sofosbuvir in US

Could be part of first all-oral regimen for virus

- PMLiVE

Lilly to invest extra $180m in US insulin manufacturing

Response to growing demand for insulin pens for people with diabetes

- PMLiVE

Janssen’s first-in-class diabetes drug Invokana wins US approval

Will be first SGLT2 inhibitor to reach the market in the States

- PMLiVE

Boehringer – Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

EMA launches diabetes drugs safety review

Will investigate pancreatitis risks in two major drug classes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links